# Metastatic Advanced Pancreas Sorafenib

> **NCT00758381** · PHASE2 · UNKNOWN · sponsor: **Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente** · enrollment: 114 (estimated)

## Conditions studied

- Locally Advanced Pancreatic Cancer

## Interventions

- **DRUG:** Sorafenib 400 mg po bid, continuously
- **DRUG:** Gemcitabina, Cisplatino

## Key facts

- **NCT ID:** NCT00758381
- **Lead sponsor:** Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2007-08
- **Primary completion:** 2008-08
- **Final completion:** 2009-08
- **Target enrollment:** 114 (ESTIMATED)
- **Last updated:** 2008-10-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00758381

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00758381, "Metastatic Advanced Pancreas Sorafenib". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00758381. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*